trending Market Intelligence /marketintelligence/en/news-insights/trending/eukhjf64qqv4vb-pxssucg2 content esgSubNav
In This List

Orthofix gets US FDA approval for foot bone implant

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Orthofix gets US FDA approval for foot bone implant

Orthofix International NV said the U.S. Food and Drug Administration granted 510(k) clearance to its G-Beam fusion beaming system to treat Charcot foot, a condition where the bones in the foot weaken and collapse.

The Lewisville, Texas-based device-maker said the G-Beam devices can be implanted in the medial and lateral columns of the foot to provide alignment, stabilization and fixation.